{"name":"Pheast Therapeutics","slug":"pheast-therapeutics","ticker":"","exchange":"","domain":"","description":"Pheast Therapeutics is a biotechnology company focused on developing innovative therapies for unmet medical needs. The company's lead candidate, PHST001, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxNZS1DclN2QlBjWTU4VkhxaHdkdG9BYzZXREJoc3p0dXFPcVl1LXg4OTRlX3dwbXY5OS1LUEg4Q0VISkpIYm15M2Z6ZTQwRHhQY09DQzIzZFJKSEFlYnhhOV8zdnN2eHlHeUdoNkY3WGRrQTJZY2JOaXEyWWtHcS12MTNBR210MHlNblhLVHR0bXY0Y0E0dUhHRGc2ZDk0dE1JRWZzYTZMMHZzcnVYckI0RENOYVg4VXdWbEF5NUNyRml1bWdzSXluMHhVTk9pNkJwWjNSUDhJaEloeC1JMW96VnlfeFZTTmRwenIzMFFaVFpZNXpPQS1wbGI5cDFQQUExVEdmdTFLOVBYNkdteEpWNHJYTXEteDJJVEpDSTNmV1UwU2drTzIzNw?oc=5","date":"2026-03-17","type":"trial","source":"Business Wire","summary":"Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-CD24 Antibody, at AACR 2026 - Business Wire","headline":"Pheast Therapeutics to Present Initial Phase 1a Clinical Data and Two New Preclinical Studies of PHST001, a Novel Anti-C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOQ2NRV01fTWhtZHJBQ1dRZ3JUdUMzalZEYU04bzFpUWlBVVZWbjJ0cXc4STEyTzI3OTZYZndYM3BJSFpla2daQm43UWdaYlhNeHBWUlc3VWJ1YzYzOUd6eTU1WU9iRV9zaU5VS1V2QU5OYXh2dXE0T1NJTTZKbHpWZC1rWUhjTURha1JQcjdPeE81WVNGa0ZUR1E5QURHaXZJLWZJdkZTT2VTcjJicTAyajJxV3hXLTRnRDlfbEFQVmljNDBxSXVOSXA0ejY?oc=5","date":"2025-07-24","type":"pipeline","source":"citybiz","summary":"Suvretta Capital Co-Leads $100M Series D for Avalyn Pharma; Catalio Capital Among Other Backers - citybiz","headline":"Suvretta Capital Co-Leads $100M Series D for Avalyn Pharma; Catalio Capital Among Other Backers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxORVM5NGNYSFVkdGpmTlNPU0JyUEtBT3l1RUxJTWQxY2pYTGQ1aGdnM2d0MVJzNzA4T3NocE1jQ2hOR2p5eVpLY0xPQzF4ZGtyVkRUV0x6cWl6dlZobm9RNjEzbGo4RDNtZlBvYldtblNIX1k1SVdsWWpQQ1lSSElnNzZaOEw5M0JCSktqR21sYktvbWt3NW9fTWtlM2NpSVVhT2lwOVcwRm9LQ25wcFNablRrMEM5ellUTFhsWXNNaWdFb3dXX3ZqYU13TnVueHNoS05weU9xcnI5NW8?oc=5","date":"2025-06-03","type":"regulatory","source":"BioSpace","summary":"Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer - BioSpace","headline":"Pheast Therapeutics Receives FDA Fast Track Designation for PHST001 for the Treatment of Ovarian Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_AFBVV95cUxPQ2k3aEpxaVVBaW9fWWVwUUFKNGVySUlhVnNNTjlXbEdiTUpSLUJXa1FyMDc3RW90UVc2NlFqa2VBSHROOVVFM3lCLU5jcmE0Ti1uNmEyY19taTg3WUlZb2E3amFvSm4wWXNhNlUzWFdPZGRRMHQ0MWJIZ2YyOXhDWHJTcFdfS2wyRi1uZTZXeXJoXzZNT0xJbzJEY1Y3Tnl0dXNjNkhMVGhwTlg3RFpUNnM0Q0F6Zms4NUd4cEtBSlNzd0o0dV9qYUpTLURYUnJTNXU3cFNEUFJMWEZwT2FXZ2JmZ3JteHBRbTZvQmNJTFBoSjZvczZpSXlOTk0?oc=5","date":"2025-04-14","type":"trial","source":"BioSpace","summary":"Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Solid Tumors - BioSpace","headline":"Pheast Therapeutics Announces First Patient Treated in Phase 1 Clinical Trial of PHST001 for Patients with Advanced Soli","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxONkNsZzBVYzVOUjI5cFdOMFJESUVSbG1FWWRFMUNYVzAtcEtkUk52Xzk1cG94a0E2M0pjNU5kMTlEdlpYSjhiMldmdG1BSzJRRlVMdjA4MGJoR1k4REtZNVpYMDhhdkZNaVpNVXZ3Ylo2ZXZXWEVWY1lQMGctcFBWS0piSllqa0plR3ZMcE9rX01tbF9R?oc=5","date":"2025-02-21","type":"pipeline","source":"Fierce Biotech","summary":"Chutes & Ladders—NIH leaders join health agency exodus - Fierce Biotech","headline":"Chutes & Ladders—NIH leaders join health agency exodus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOT0plUGJfNzdXY01Wcm56bW1TYjQtSlYyTHBZT1o3SWlhTXVzOU5Kam5BM2JSdl9mQmNWNnRWOTViSGdRSVhFSFZ2WnZmLUI1YS1OTEZ3bUZTOXQ5eG0zbW9HZ2ZZMlBTVWt0cFpfdVRkUzZaZ1J3V2xoanBLOVFSTm01MlloLTFlaWlIdHBldDc?oc=5","date":"2025-01-21","type":"trial","source":"Endpoints News","summary":"China's biotech boom is threatening US drugmakers' dominance - Endpoints News","headline":"China's biotech boom is threatening US drugmakers' dominance","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQcWtaSEw3eW1Xczg3VWk5WUFlZVdXdmppd3MzS0JlbDZXcW9jY2FlazlmMmVjUHpDcnhBREJwNHoyeXgtSUJ4S1lLcDdZbGxQbGtfZ1JTTVR3X0VONTVOSkdPS3E4ZjhPSy1aMUR2VVVEYWdLLTZBV0FuaElDNExyc19TbDBqa0tiOENFbXpn?oc=5","date":"2023-06-07","type":"pipeline","source":"BioPharma Dive","summary":"With new startup Bitterroot, Forty Seven founder takes aim at heart disease - BioPharma Dive","headline":"With new startup Bitterroot, Forty Seven founder takes aim at heart disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxNUWJLWG1KdDdnYnRldm94UmlQUjlodzllWUNWWjN1bzVwUDFRV2wxVUlfNW0zY21QYkhRQ1ZxZHVrSlVLMEZHQTJvdkN5NDNVZjZVTDB4NkE0RGl2Qm9TcE14dGwxWXRveUxFVU8zel9RR0pfNHd3Nl9oMThrQnF6YTJfbld0aDU1Z0lpbUtqWkxyUjVZ?oc=5","date":"2023-02-17","type":"pipeline","source":"Pharma Voice","summary":"Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies - Pharma Voice","headline":"Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxOU1M1UXRLcHpIR3BNdE93UjROcEVCS3M2R1JjMjlia0pWYklnQmdJbmZPSjkxRkdsckQzczVLOWVOMTRieWRyV3lveWNNVVI2NnBrNVM1N1dUbklweVVSc3hVVnozN3l2dldMUlNYT2FwanI2UWZyRGVnZXppazRndHZqYjloRlNnd0MxMUhYMms5NFFiNEpZRU1tazROQXpvYnhieGFiUVlSellZb3JPdzhTRVZteHlPU3VPMFBzUHRqaE1xdkJZUVczclJLNktNbGthaVhB?oc=5","date":"2022-04-26","type":"pipeline","source":"PR Newswire","summary":"Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer - PR Newswire","headline":"Pheast Raises $76M in Series A Funding to Train the Immune System to Feast on Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxNd1FSd0RnNDdVaEZIYXhfY3pzMXAyNVYzTWtWRy1adjdzcnhPMTZnaFpzUVg2SE5xUUZSclBITHpxSHZTT2ZGUWhGYTl5WGQwaTNDMDRXMjdtM25nWVhLX05tZ3E5OXB2ZVZqUnpVaTZvUHJxZU9GckpuRGtuUTZ0MDdsN014ZjQ2eHVqMW1yNnlQWndBUlFLc0d2b2tVOGY1NWpIVVBR?oc=5","date":"2022-04-26","type":"pipeline","source":"Fierce Biotech","summary":"Ready to eat: Investors fork out $76M for Pheast's cancer therapies - Fierce Biotech","headline":"Ready to eat: Investors fork out $76M for Pheast's cancer therapies","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}